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Abstract
Background: Autism is a behavioral disorder with impaired social interaction, communication,
and repetitive and stereotypic behaviors. About 5–10 % of individuals with autism have 'secondary'
autism in which an environmental agent, chromosome abnormality, or single gene disorder can be
identified. Ninety percent have idiopathic autism and a major gene has not yet been identified. We
have assessed the incidence of chromosome abnormalities and Fragile X syndrome in a population
of autistic patients referred to our laboratory.
Methods: Data was analyzed from 433 patients with autistic traits tested using chromosome
analysis and/or fluorescence in situ hybridization (FISH) and/or molecular testing for fragile X
syndrome by Southern and PCR methods.
Results: The median age was 4 years. Sex ratio was 4.5 males to 1 female [354:79]. A chromosome
(cs) abnormality was found in 14/421 [3.33 %] cases. The aberrations were: 4/14 [28%]
supernumerary markers; 4/14 [28%] deletions; 1/14 [7%] duplication; 3/14 [21%] inversions; 2/14
[14%] translocations. FISH was performed on 23 cases for reasons other than to characterize a
previously identified cytogenetic abnormality. All 23 cases were negative.
Fragile-X testing by Southern blots and PCR analysis found 7/316 [2.2 %] with an abnormal result.
The mutations detected were: a full mutation (fM) and abnormal methylation in 3 [43 %], mosaic
mutations with partial methylation of variable clinical significance in 3 [43%] and a permutation
carrier [14%].
The frequency of chromosome and fragile-X abnormalities appears to be within the range in
reported surveys (cs 4.8-1.7%, FRAX 2–4%). Limitations of our retrospective study include paucity
of behavioral diagnostic information, and a specific clinical criterion for testing.
Conclusions: Twenty-eight percent of chromosome abnormalities detected in our study were
subtle; therefore a high resolution cytogenetic study with a scrutiny of 15q11.2q13, 2q37 and
Xp23.3 region should be standard practice when the indication is autism. The higher incidence of
mosaic fragile-X mutations with partial methylation compared to FRAXA positive population [50%
vs 15–40%] suggests that faint bands and variations in the Southern band pattern may occur in
autistic patients.
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Background
In 1943 Kanner coined "infantile autism" (autism derived
from Greek autos, or self) after observing 11 children,
mostly boys, on the basis of their social isolation. Autism,
often referred to as autistic disorder or infantile autism, is
a complex behavioral disorder, which, by definition,
develops prior to age three. Autism is defined completely
on the basis of impairments in social interaction and com-
munication, repetitive and stereotypic behaviors. Recent
research has examined autistic traits in a population of
twins and found that social impairment actually follows a
unimodal distribution without a clear demarcation to
separate cases of the disorder [1]. For this reason, future
discussion of autism may be referred to as autism spec-
trum disorder (ASD) [2].
For most children, the onset of autism is gradual; how-
ever, about 30% have a "regressive" onset. Fifty to seventy
percent of children with autism are defined as mentally
retarded by nonverbal IQ testing. Seizures develop in
about 25% of children with autism. About 25% of chil-
dren who fit the diagnostic criteria for autism at age two
or three years subsequently begin to talk and communi-
cate, and by six or seven years blend to varying degrees
into the regular school population. The remaining 75%
continue to have a life-long disability requiring intensive
parental, school, and societal support. There are no bio-
logic markers, therefore the standard criteria, compiled by
the American Psychiatric Association Manual of Psychiat-
ric Diseases, 4th edition (DSM-IV), is the primary diag-
nostic reference used in the United States for autism. The
causes of autism can be divided into "idiopathic," which
comprises the majority of cases, and "secondary," in
which an environmental agent, chromosome abnormal-
ity, or single gene disorder can be identified. About 5–
10% of individuals with autism can be diagnosed with
secondary autism; the remaining 90–95% have idiopathic
autism. About 30% of children with idiopathic autism
have complex autism, defined by the presence of dysmor-
phic features or microcephaly or a structural brain malfor-
mation [3]. About 70% of children with idiopathic autism
have essential autism, defined as the absence of physical
abnormalities.
A recent CDC case-finding study in Brick Township, New
Jersey reported prevalence at 40 per 10,000 for autism [4].
While the latest epidemiologic study from the United
Kingdom utilizing specialized visiting nurses who moni-
tored child health and development at seven months, 18
to 24 months, and three years of age reported a prevalence
rate of 16.8 per 10,000 for autism [5]. The sex ratio for
autism has been estimated at 4 males:1 female [6,7].
Social cognition and communication in autism may be
related to dysfunction in the amygdala, hippocampus,
and related limbic and cortical structures. The cerebellum
may also form part of a distributed neuronal network
responsible for social cognition and communication.
Serotonin is the neurotransmitter implicated in autism [8]
The single gene disorders in which secondary autism is
observed include fragile X syndrome, tuberous sclerosis,
phenylketonuria, Rett syndrome [3,9], Sotos, Neurofi-
bromatosis I, Joubert syndrome [10], and Smith-Lemli-
Opitz syndrome [11]. Risk to sibs of idiopathic cases is 75
times greater than the prevalence in the general popula-
tion [7] and higher concordance for autism among
monozygotic (60–90%) than dizygotic (0–10%) twins
[12] argue for a genetic predisposition to idiopathic
autism. Multiple independent whole genome scans and
chromosomal abnormalities studies have pointed out sev-
eral candidate regions on chromosomes 2q, 3q, 7q, 6,
13q, 15q, 16p, 17q and sex chromosomes. These regions
possess candidate genes that have been screened for muta-
tions or association with autism [13]. However, a clear
involvement of a major susceptibility gene (or genes) in
autism remains far from clear. The results from linkage
studies and the drop in the concordance rates between
monozygotic and dizygotic twins suggests that the genetic
etiology of autism is certainly heterogeneous (different
genes in different families), polygenic (more than one
affected gene per individual) with epigenetic influences
and allelic heterogeneity (different variants in the same
gene may lead to different patterns of genetic disease) [13-
15].
To gain further insight into secondary autism we have
compiled data on patients with autistic traits tested for
fragile-X syndrome using molecular methods and chro-
mosome abnormalities using cytogenetic analysis and
FISH.
Methods
A search was initiated using the key word autism in the
indication field of the Genzyme Genetics, Orange labora-
tory database. For each case the electronic data and/or
files were reviewed. The referral center, age, sex, karyotype,
fluorescence in situ hybridization (FISH) and fragile X
results were extracted and tabulated.
Table 1: Demographics of the ASD patients tested
Demographics
Patients with ASD referred for genetic testing = 433
Median age = 4 years
Sex ratio = 4.5 males to 1 femaleBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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G-banded metaphases were prepared using standard pro-
cedures and FISH was performed using the protocol pro-
vided by the manufacturer of the commercial probes
(Vysis Inc., Illinois, MI).
Fragile X test: Isolated DNA was tested by both Southern
blot analysis and Polymerase chain reaction (PCR) for the
size and methylation status of the CGG repeat expansion
within the FMR-1 gene. Southern blot analysis was per-
formed with the probe StB12.3 on EcoR1 and Eag1
digested DNA. PCR products were separated by acryla-
mide gel electrophoresis and detected with a CGG repeat
probe.
Results
Patients with autistic traits were referred by physicians to
our laboratory for genetic testing. The clinical diagnostic
criteria applied were not specified on the test request
forms.
A total of 433 patients with an indication of autism were
sent to our laboratory for genetic diagnosis. The median
Table 2: The chromosome abnormality found in 3.33 % (14/421) patients with an indication of autism
Sl # Age Sex Clinical Indication Chromosome Result FISH Result Fragile 
X Result
Marker 4/14 = 28%
1 6.1 M Autism 47,XY,+mar[27]/46,XY[3] .ish der(2)(D2Z+) NRM
2 5 F Autism 47,XX,+mar .ish der(15)(D15Z+,D15S11++, 
GABRB3+)
NT
3 3 M Autism 47,XY,+mar de novo .ish 
i(15)(q11.2)(rRNA++,D15Z+,D15S11-)
NT
4 5.1 F Autism, MR mos47,XY,+r[15]/46,XX[15] .ish 
der(15)(rRNA+,D15Z+,D15S11+,GABR
B3+).
NT
Duplication 1/14 = 7%
51 6 . 7
5
F Autism 46,XX,dup(15)(q11.2q13)de novo .ish 
dup(15)(q12)(D15S11++,GABRB3++)de 
novo
NT
Deletion 4/14 = 28%
6 6.5 F Autism, DD, MR, 
macrocephaly
.ish del(2) (q37.3)(D2S447-) NT
7 6.6 F Autism, DD 46,XX,del(3)(p25) de novo NT
8 11.7 M Autism, DD, MR, multiple 
congenital abnormality, h/o DS
46,XY,del(12)(q21.2q23.3) .ish 12(wcp12x2) NRM
9 3.6 M Autism 46,XY,del(13)(q13.2q14.1)de novo .ish 13q13(D13S6x2),13q14(RBx2) NT
Inversion 3/14 = 21%
10 2.8 F Autism 46,XX,inv(10)(p11.2q21.2)* NT NRM
11 3.5 M Autism Mos46,XY,inv(14)(q11.2q33)[3]/
46,XY[17]*
NT NRM
12 3.25 M Autism, hypotonia, DD 46,XY,add(17)(q23) or 
inv(17)(q23q25)de novo
.ish 
inv(17)(q24.2q25.3)(wcp17x2,MPOx2,D
17S928x2)
NT
Translocation 2/14 = 14%
13 2.7 F Autism 46,XX,t(1;14)(q25;q31.2) NT NT
14 3.3 M Autism 46,XY,der(14;18)(q10;q10) NT NRM
DD = developmental delay, MR = mental retardation, DS = Down syndrome, NT = not tested NRM = normal *inv(10) is a normal familial variant 
and inv(14) is a frequently observed artifact of cultureBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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age was 4 years. Sex ratio was 4.5 males to 1 female
[354:79] (Table 1). A chromosome abnormality was
found in 14/421 [3.33 %] cases. A Fragile-Xq27.3 was
diagnosed in 7/316 [2.2 %].
Chromosome abnormalities are summarized in Table 2:
The aberrations were: 4/14 [28%] supernumerary markers
from cs 15 [3] and cs 2 [1] (Fig 1a); 4/14 [28%] deletions
of 2q37.3, 3p25, 12q21.2q23.3 and 13q13.2q14.1(Fig
1b); 1/14 [7%] duplication of 15q11.2q13; 3/14 [21%]
inversions of 10p11.2q21.2, 17q23q25 (de novo) and
14q11.2q33 (mosaic) (Fig 1c); 2/14 [14%] translocations,
one balanced t(1;14) and one unbalanced der(14;18) (Fig
1d).
The 3/4 marker/ring had a 15 centromere signal by FISH
and had either nil, one or two signals for D15S11, that
demarcates the involvement of the critical region of
Prader Willi/Angelman syndrome (Table 2).
Fluorescence in situ hybridization was performed on 23
of 433 patients for reasons other than to characterize a
cytogenetic abnormality, 3 to rule out Williams-Beuren
Syndrome, 5 for DiGeorge syndrome, 7 for proximal
duplication of D15S11, 6 for subtelomere rearrange-
ments, 1-for subtelomere rearrangement & proximal
duplication D15S11 and 1 for duplication D15S11,
Smith-Magenis Syndome, and DiGeorge Syndrome. All
23 FISH tests were negative (Table 3).
Fragile X (Table 4): The mutations detected were: A full
mutation (fM) and abnormal methylation in 3 [43 %]
and mosaic mutations with partial methylation of varia-
ble clinical significance in 3 [43%]. The mosaic size muta-
tions were: an fM [200–900 repeats(r)] / deletion
mutation [30 r] with partial methylation. The faint bands
for the full mutation and deletion mutation may be a
reflection of the sample quality (Fig 2, Lane 5). Two size
mosaics had permutation (pM) [150 r]/fM [400 r] (Fig 2),
and pM [155 r]/fM [800 r] with normal and abnormal
methylation. A premutation mosaic female carrier with an
atypical EcoR1 and Eag1 pattern and a typical BssH1 pat-
tern gave 2.8, 3.0, 5.2–5.4 Kb bands, the Eag1 pattern sug-
gested a DNA sequence change [14%]. PCR gave
reproducible bands corresponding to 29, 65, 80 repeats
and a faint band for 39 repeats. Intermediate mutation
(45–54 r) was found in 5 males and 2 females.
Table 3: Summary of FISH cases
Sl # Age in
years
Sex Clinical Indication Karyotype FISH FRAX
1 5.25 M Autism 46,XY Normal ish 7q11.23(ELNX2)
2 7 M Autism, FTT, MR, DD 46,XY Normal ish 7q11.23(ELNX2) NRM
3 M Autism 46,XY Normal ish 7q11.23(ELNX2) NRM
4 3.6 M Autism, DD, hypocalcemia, cardiac defect, MR 46,XY Normal ish 22q11.2(TUPLEx2)
5 6.3 M Autism, DD, hypotonia 46,XY Normal ish 22q11.2(TUPLEx2)
6 3.5 M Autism not ordered Normal-ish 22q11.2(TUPLEx2)
7 M Autism 46,XY Normal-ish 22q11.2(TUPLEx2)
8 M Autism 46,XY Normal-ish 22q11.2(TUPLEx2) NRM
9 6.5 M Autism, DD, MR 46,XY Normal, ish 15q12(D15S11x2) NRM
10 11.6 M Autism, DD 46,XY Normal, ish 15q12(D15S11x2) NRM
11 3.5 M Autism 46,XY Normal, ish 15q12(D15S11x2) NRM
12 3 M Autism 46,XY Normal, ish 15q12(D15S11x2)
13 2 M Autism, DD,MR 46,XY Normal-ish 15q12(D15S11x2) NRM
14 2.5 F Autism, DD,MR 46,XX Normal ish 15q12(D15S11) NRM
15 3.6 M Autism, DD, patch hyperpigmentation 46,XY Normal, ish 15q12(D15S11x2) NRM
16 3.5 M Autism, DD, seizures 46,XY Normal- subtelomere panel NRM
17 3.5 F Autism, DD 46,XX Normal-subtelomeres NRM
18 4.6 M Autism, DD 46,XY Normal-subtelomeres NRM
19 8.6 M Autism, DD 46,XY Normal-subtelomeres NRM
20 M Autism 46,XY Normal-subtelomeres NRM
21 2.7 M Autism 46,XY Normal-subtelomeres ABN
22 16 M Autism, DD, dysmorphic features, MR 46,XY Normal, subtelomeres Normal, ish 
15q12(D15S11x2)
23 17.5 F Autism 46,XX Normal ish 15q11.2q13(D15S11x2), 
17p11.2(SMSx2), 22q11.2(TUPLE1X2)
M = male, F = female, NRM = normal, ABN = abnormal, DD = development delay, MR = mental retardation, FTT = failure to thrive.BMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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Discussion
Chromosomal causes of secondary Autism Spectrum 
Disorder (ASD)
About 1.7 % to 4.8 % of individuals with ASD have chro-
mosome abnormalities, including unbalanced transloca-
tions, inversions, rings, and interstitial deletions and
duplications (Table 5). The chromosome abnormalities
that have been reported on more than one occasion are
duplication of 15q, deletions of 18q, Xp, 2q and the sex
chromosome aneuploidies 47,XYY and 45,X [16].
A recent FISH subtelomere study found one out of ten
unselected patients with ASD had a subtelomeric 2qter
deletion [17]. In our experience 7/7 ASD patients were
negative for subtelomeric rearrangements.
Children with Down syndrome have autism more com-
monly than expected. The incidence was at least 7 % in
one study [18]. This finding suggests that chromosome
abnormalities may lower the threshold for the expression
of autism.
In our study (4/14 = 28 %) and in other surveys, the com-
mon recurring chromosomal abnormality was duplica-
tion of the proximal 15q region (Table 5). About 1% of
individuals with ASD have a chromosomal duplication in
the Prader-Willi/Angelman region of proximal 15q
[[19,20], present study 4/421[0.95%]]. The duplicated
region q11.2q13 is on the maternal chromosome 15 in
autistic patients [21-23]. Most commonly, this is a super-
numerary isodicentric 15q chromosome detectable by
routine cytogenetic studies or, less commonly, an intersti-
tial duplication of the region detected by FISH analysis for
the SNRPN gene region. These two chromosome abnor-
malities have only subtle effects on the physical pheno-
type. Supernumerary isodicentric 15q chromosomes are
de novo occurrences. Duplication of proximal 15q may
result from segregation of a parental chromosome translo-
cation or an interstitial 15q duplication. An abnormal
gene dosage within 15q11.2-q13 might cause susceptibil-
ity to autism.
The 15q11-q13 region is shown schematically in Figures 3
&4. Chromosome 15q11.2-q13 has gained support as an
autism candidate region on the basis of the association of
maternally derived chromosomal duplications of this
region with an autistic phenotype [20,24-27] and genetic
evidence for linkage and allelic association in the same
interval in chromosomally normal autism families [28-
34]. The maternal specificity of chromosome 15 duplica-
tions in autism suggests a genomic imprinting effect.
There are multiple imprinted genes in 15q11.2-q13, and
two neurodevelopmental disorders exhibiting opposite
patterns of genomic imprinting have been mapped to this
region [35-37]. Interstitial deletion of 15q11.2-q13
specific for the paternal chromosome is the most frequent
cause of Prader-Willi syndrome (PWS; MIM 176270),
whereas maternal-specific deletion of the same common
interval results in Angelman syndrome (AS; MIM
105830). The converse of Angelman Syndrome is
observed in autism, that is a maternal duplication. The
four causes of Angelman syndrome are 1) maternal dele-
tion of 15q11.2q13, 2) paternal UPD15 3) mutations in
UBE3A 4) mutations leading to imprinting errors of this
region. A population-based study showed a high rate of
ASD in AS [38]. But, a mutation was not identified in the
UBE3A putative promoter or coding region in 10 idio-
pathic ASD patients [39]. Lack of expression of the mater-
nally expressed UBE3A gene in the brain is thought to be
the cause of AS. Since patients with deletions compared to
other types of AS mutations have a more severe
Mosaic fragile X mutations: Southern blot using probe  StB12.3 on EcoR1 and Eag1 (methylation-sensitive enzyme)  digested DNA Figure 2
Mosaic fragile X mutations: Southern blot using probe 
StB12.3 on EcoR1 and Eag1 (methylation-sensitive enzyme) 
digested DNA. Lane 1 – permutation carrier, Lane 2 & 3 – 
normal female, Lane 4 – normal male, Lane 5 – an ASD male 
mosaic with fm (3.7 and 5.8–7.9 kb, 200–900 r)(arrows)/a 
deletion mutation (2.8 kb faint band, 30 r)(arrow). By PCR a 
30 repeats and >200 repeats were amplified. Lane 6 – an 
ASD male mosaic fm (6.4 kb, 400 r)/pm (3.3 kb, 150 r).BMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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Chromosome abnormalities in patients with autistic traits (A) 4 markers Figure 1
Chromosome abnormalities in patients with autistic traits (A) 4 markers: [multiple copies] derived from chromosome 2 [1], 15 
[3] with nomenclature (B) 1 duplication of chromosome 15 with arrow denoting the region involved (C) 3 partial deletions 
(right homolog)(multiple copies) of 3p25, 12q21.2q23.3 & 13q13.2q14.1 with the ideogram, the arrows denote the deleted 
region. (D) 3 inversions (the right homolog) (multiple copies), inv(10)(p11.2q21.2), inv(14)(q11.2q32), inv(17)(q24.2q25.3) with 
arrows on the ideogram showing the inverted region (E) 2 translocations (partials in 2 copies, chromosomes involved (right) 
and their normal homolog (left)) one apparently balanced t(1;14)(q25;q31.2) and one unbalanced der(14;18)(q10;q10). The ide-
ogram with arrows show the breakpoints
BBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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phenotype, suggests the involvement of additional gene
losses, such as GABAA receptor gene cluster [40]. Tran-
scripts increased in patients with duplications
15q11.2q13 are maternal UBE3A [41], maternal ATP10C
[40,42] and other transcripts including antisense tran-
scripts that could regulate gene expression [43] and may
contribute to the duplication phenotype. Therefore, over
expression of genes in 15q11-q13 probably confers ASD
risk. Region proximal to D15S11 is considered to have no
phenotypic effect. However, one of our patients had a
marker 15 negative for D15S11, therefore, some duplica-
tions of 15, proximal to D15S11 and the autism candidate
region may also influence susceptibility to autistic traits.
Initial studies to characterize the phenotype of
15q11.2q13 duplication patients have found variation
among affected people including mental retardation,
motor coordination problems, seizure disorder, and
impairments in attention, communication, and social
function (some but not all with ASD or attention deficit
hyperactivity disorder (ADHD)) [44,45]. It appears there
may be a parent-of-origin effect on the linkage and associ-
ation signals in this region of UBE3A and ATP10C
[46,32,33]. Further studies across data sets, and rigorous
evaluation of potential functional effects of associated
alleles, and a thorough assessment of haplotype
transmission within ATP10C and neighboring genes
would be conclusive. The majority of linkage and associa-
tion data point to the GABRB3 gene, which is one of a
cluster of γ-aminobutyric acid (GABA) receptor subunits
that map to the distal, apparently nonimprinted segment
of the duplicated region (Fig. 3). Although a number of
groups have detected genetic effects at GABRB3 in inde-
pendent autism populations [29-31], other studies have
failed to replicate these observations [47-49].
Yardin et al 2002 [50] recommended a systematic screen-
ing by FISH, of chromosome region 15q11.2q13 in cases
with autistic-like syndrome
A deletion of 2q37.3 was identified by FISH in a patient
with autism and macrocephaly in our study. Wolff et al
2002 [51] also reported an autistic patient with a 2q37.3
deletion detected using subtelomere probes. Whole
genome screens have suggested several chromosomal
regions that are potentially associated with a susceptibility
gene for autism. [52-57]. Three studies revealed positive
linkage to 2q [52,53,57] and a third study demonstrated
linkage to distal 2q in a subset of patients with autism and
delayed onset of phrase speech [53]. Genomic scans are
limited by the number of loci that are assessed; therefore,
not all areas may be equally represented. It is important to
note that telomeric regions may have increased meiotic
recombination and may be under-represented in these
types of analyses. Thus, the FISH approach is an important
correlative study in the search for susceptibility genes.
Macrocephaly in ASD: most children with autism are born
with normal head circumference and about 20% meet the
Table 4: The details of Fragile X mutations found in 2.2 % (7/316) patients with a clinical indication of autism
Sl # Age In 
years
Sex Clinical indication FRAXA Result Methylation Chrom 
Result
FISH 
Result
Full mutation 3/7= 43%
1 4.5 M Autism ABN-Full mutation (400,533,667repeats [r]) abnormal methylation 46,XY NT
2 5 M Autism ABN-Full mutation (600–1100 r) abnormal methylation 46,XY NT
3 4.5 M Autism, DD ABN- Full mutation (267–933 r), abnormal methylation 46,XY NT
Mosaic mutation 3/7 = 43%
4 2.3 M Autism ABN-size mosaic Full mutation [800 r]/ premutation 
[155 r]
Normal & abnormal 
methylation
46,XY NT
5 1.7 M Autism ABN-size mosaic Full mutation [400 r]/ premutation 
[150 r]
Normal & abnormal 
methylation
46,XY Normal
-sub tel
6 8.5 M Autism, DD ABN-mosaic Full mutation [200–900 r]/ deletion 
mutation [30 r],
partial methylation 46,XY NT
Mosaic Premutation carrier 1/7 = 14%
7 6 F Autism ABN- premutation mosaic [29,65,80,39(light band)r] 46,XX NT
Av 4.36 
years
2F, 
5M
Intermediate mutation  7 cases with 45–54r
DD = developmental delay, NT = not testedBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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Table 5: Summary of reported population studies to assess the frequency of chromosome abnormalities (excluding fragile sites, 
polymorphisms and single cell abnormalities)
Study Subjects 
karyotyped
Chromosome abnormality Clinical diagnosis
Konstantareas & Homatidis 1999 
[123]
127 6 [4.7%] Diagnosed using the clinical criteria of autistic 
disorder by DSM-III (1983–1989)
46,XY,inv(2)(p11q13)pat,3q+
47,XY,+mar
47,XY,+mar
47,XX,+13
47,XX,+inv dup(15)(pter→ q13::q13→ 
pter)
47,XY,+der(15)(pter→ q15::p11→ 
pter)de novo
Gillberg & Wahlstrom 1985 
[124]
46 2 [4.3%] Diagnosed using the American Psychiatric 
Association (1980) criteria DSM-III
47,XY,+21
47,XYY
Lauritsen 1999 [122] 145 4 [2.8%] Cases with psychotic symptoms before 2–3 years or 
beginning at 2–3 or later between 1969–1993
47,XX,+mar,?t(13;22)
46,XX,t(9;10)(p23;q23.1)
46,XY,inv(10)(p11.21;q21.2)mat
46,XY,t(7;12)(q21.4;q15)de novo
Li 1993 [121] 104 5 [4.8%] Diagnosed using the American Psychiatric 
Association (1980 & 1987) guidelines, DSM-III & III-R
47,XY,+21
46,XY/47,XY,+21 [12/88]
46,XY,t(5;6)(q13;p23)de novo
46,X,inv(Y)(p11q11)
46,fra(X)(q27.3),inv(Y)(p11q11)
Weidmer-Mikhail 1998 [120] 59 1 [1.69 %] DSM-III-R (1991–1995)
Tetrasomy 15
Ritvo 1990 [6] 233 9 [3.9%] DSM-III (1984–1988)
6-trisomy 21
Partial trisomy 8
Deletion 9p
46,XX,t(5q;11q)pat
Wassink 2001 [119] 278 13 [4.7 %] DSM-III,-III-R & -IV (1980–1999)
46,XX,del(8)(p23) MR, diaphragmatic hernia, hemivertebra, 2-vessel 
umbilicus, strabismus
47,XX,der(14)t(14;?)(q22;?) MR, abnormal facies & palate, failure to thrive
46,XX,dup(15)(q11.2;q13) MR, abnormal EEG, precocious puberty
2–46,XY,del(15)(q11.2q13) Mild MR Moderate MR & Seizures
mat47,XX,+mar de novo 47,XX,+mar McCune-Albright syndrome Microcephaly, abnormal 
facies
47,XY,+del(15)(q22) MR
46,XY,del(16)(q13q22) MR, Seizures, failure to thrive, abnormal facies, 
webbed neck macrocephaly, syndactyly
46,XY,add(17)(q23) MR & abnormal facies
2–47,XX,+21 MR, heart murmur, esotropia, recurrent pneumonia. 
MR1VSD, pneumonia and seizures
46,XY,add(22)(q13) Macrocephaly and failure to thrive
Present 421 14 [3.3%] Physician referrals to a genetic lab. 1995–2003 
MarchBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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criteria for macrocephaly [58]. The increased rate of
growth in head circumference appears to be most dra-
matic in the first year of life and corresponds to increased
growth of the cerebral cortex as measured by MRI [59].
A de novo deletion of chromosome 3, del(3)(p25), was
found in one case with ASD and development delay in our
patient pool. A deletion of 3q region was found by Kon-
stantareas & Homatidis 1999 [60]. Genome wide scan
found a major susceptibility locus at 3q25-27 and there
was also allelic association in families with autism spec-
trum disorder originating from a subisolate of Finland
[61,62]. Animal models and linkage data from genome
screens implicate the oxytocin receptor at 3p25-p26
[61,62].
To date, there have been no reports of 12q deletions in
patients with ASD, to the best of our knowledge. For the
first time we report an interstitial deletion
46,XY,del(12)(q21.2q23.3) in a patient with ASD, devel-
opment delay, mental retardation, multiple congenital
abnormality, and family history of Down syndrome.
46,XY,del(13)(q13.2q14.1)de novo was found in one of
our patients' with ASD. Hyperserotonemia in autism is
one of the longest-standing biochemical findings. The
Chromosome 15q11-q13 region showing the autism candidate region Figure 3
Chromosome 15q11-q13 region showing the autism candidate region. A schematic representation of the 15q11-q13 interval 
duplicated in autism cases and deleted in Prader-Willi/Angelman syndrome is shown. IC denotes the position of the 15q 
imprinting center. Loci corresponding to previous reports of linkage and association are indicated by dark and light arrow-
heads, respectively, below the map. (Adapted with permission from Sutcliffe J et al article "Dense linkage disequilibrium map-
ping in the 15q11-q13 maternal expression domain yields evidence for association in autism' in Molecular Psychiatry (2003) 8, 
624–634)BMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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serotonin 2A receptor gene (HTR2A) on chromosome
13q14q21 is a primary candidate gene in autism. Con-
verging data from recent genome screens also implicates
the genomic region containing HTR2A [63-66]. Correla-
tion of HTR2A disruption or deletion in our case with a
13q13.2q14.1 deletion and other 13q deletion in ASD
patients would complement genome screen data.
The recent physical mapping of the serotonin 5-HT(7)
receptor gene (HTR7) to 10q23 [67] raises the question if
the inversion inv(10)(p11.2q21.2) present in our patient,
which is considered a normal familial variant could have
long range influence on HTR7 and susceptibility to autism
in some cases.
So far there has been no observed association or link
between chromosome 14 and ASD. Also, the mosaic
inversion inv(14)(q11.2q33) [3/20] found in one of our
patients is considered a cultural artifact when seen in 1or
2 cells.
In this study, a patient with inv(17)(q23q25)de novo,
had ASD, hypotonia and developmental delay. Chromo-
some 17q shows association with autism by genome wide
scans and in linkage studies [57,66,68]. There is also inter-
est in 17q since serotonin transporter gene (SERT) has
been mapped to17q11-q12 [69].
We report a patient with 18p deletion due to an unbal-
anced translocation between 14 and 18. Majority of the
reported cases with autism involve deletion of 18q [70-
The map location of D15S11 probe used to characterize the markers Figure 4
The map location of D15S11 probe used to characterize the markersBMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
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72]. A deletion of the 18p-arm (at band 11.3) in about
50% cells and 50% of the cells with a duplication of the
long arm in peripheral blood was described in a mildly
obese girl with DSM-III-R autistic disorder and moderate
mental retardation [73]. Another preschool girl with
selective autism and a deletion of Chromosome 18p11.l
has also been described [74]. She had communication
problems consistent with a diagnosis of autism. However,
in the area of reciprocal social interaction she was a little
less deviant than most children and had no major behav-
ior problems typical of autistic disorder. Linkage and asso-
ciation studies have suggested at least 2 candidate loci,
one on the short and the other on the long arms of chro-
mosome 18 [75].
One of the breakpoints in the balanced translocation,
46,XX,t(1;14)(q25;q31.2) was 1q25, in the present study.
A recent report, links D1S1675 that maps to chromosome
1q24 with autism [76] using obsessive-compulsive behav-
iors as a restricting criterion for the analysis. The
proximity of our breakpoint and D1S1675 may be coinci-
dental or causal.
Although no cases with X- rearrangements were identified,
in this study, the literature on abnormal X chromosome
and autism is discussed as it has been cited in multiple
cases. An autistic (ICD-10) woman had a translocation,
t(X;8)(p22.13;q22.1) [77], a boy with "autistic disorder"
had duplication of Xp22 [78], and a de novo Xp22.3 dele-
tion was observed in 3 autistic females [79]. Further,
mutations in cell adhesion genes NLGN4 on Xp22.3 and
NLGN3 on Xq13 are reported in patients with autism
[80]. Therefore, subtle Xp rearrangements have to be con-
sidered in the cytogenetic assessment of ASD patients
Fragile X syndrome
The typical clinical picture in FRAXA includes mental
retardation, macro-orchidism, large ears, and prominent
jaw. Within neurons, the FMR protein (FMRP) interacts
with mRNA and ribosomes, suggesting a role in regulating
protein synthesis [81]. FMRP is heavily synthesized in
dendritic spines in response to synaptic activity, and
abnormal dendritic spine size and shape have been noted
in FRAXA patients and fmr1 knockout mice [82]. These
abnormalities may correspond to an abnormal postsyn-
aptic response that weakens synaptic connections [83].
A multicenter study in Sweden [84] found fragile X in 13
of 83 boys (16%) with infantile autism but in none of 19
girls with infantile autism. Klauck et al. (1997) [85] con-
cluded from molecular genetic studies of 141 patients
from 105 simplex and 18 multiplex families that an asso-
ciation of autism with fragile X is nonexistent and that the
Xq27.3 region is not a candidate for autism. Stoll (2001)
[86] presented 11 children under the age of 8 years and
the difficulties in diagnosis of fragile X syndrome at this
age. The author concluded on the importance of fragile X
DNA test for all children with mental retardation, autism,
or significant developmental delay without a clear etiol-
ogy. Whereas only a few percent of children with autism
have fragile X syndrome, at least half of children with
fragile X syndrome have autistic behaviors, including
avoidance of eye contact, language delays, repetitive
behaviors, sleep disturbances, tantrums, self-injurious
behaviors, hyperactivity, impulsiveness, inattention, and
sound sensitivities. The frequency of the fragile X syn-
drome among individuals with autism was ascertained up
to 1993 using cytogenetic method. The incidence ranged
from 12.7%–1.6%. However, these studies had different
criteria for classifying positive cases. The differences were:
the number of metaphases analyzed ranged from 20 to
100 and the cut-off range from 1% to 4% metaphases with
a fragile X [84,87-94]. Using molecular analysis the inci-
dence of fragile X syndrome was 5% (1/20) [95], 3.3%(1/
30) [96], 12% (3/25) [97] and the present study 2.2 % (7/
316). The difference in incidence between the present
(2.2%) and previous studies (3.3% – 12%) may be due to
small sample size in the other studies or clinical criteria
for selection of patients or both.
Mosaicism for FRAX mutation: 
Forty-three percent of FRAX patients had a mosaic muta-
tion in our study. The prevalence of males who carry a full
mutation and a permutation is 15–20% [98-102] among
the affected individuals. Nolin et al 1994 [103] analyzed
a group of affected fragile X males by Southern blotting
and found 41% (61/148) to be mosaic. This observation
of 41% is significantly higher than previous reports 15–
20%. The difference could be technical modifications,
which permitted the identification of faint premutation
bands in some patients. The higher percentage (43 %) of
affected males with mosaicism in our study suggests that
the occurrence of such individuals may be frequent in
patients with ASD.
The degree of mental retardation seemed not to be influ-
enced by the presence of premutation alleles in some of
the cells and a full mutation in the rest of the cells [104].
While Merenstein et al 1996 [105] study suggests there
may be some variation of clinical expression in fragile X
males with a full mutation and permutation. It has been
hypothesized that these mosaic cases should show higher
levels of functioning than those who have only the inac-
tive full mutation gene, but previous studies have pro-
vided negative or equivocal results. In one study, the
cross-sectional development of communication, self-care,
socialization, and motor skills was studied in 46 males
with fragile X syndrome under age 20 years as a function
of two variables: age and the presence or absence of mosa-
icism. The rate of adaptive skills development was 2–4BMC Medical Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2350/6/3
Page 12 of 16
(page number not for citation purposes)
times greater in mosaic cases versus full mutation cases.
FMR1 protein (FMRP) levels was shown to correlate with
IQ, even in mosaic males for 38% of the IQ variance
[106,107]. There was also a trend for cases with autism to
be more prevalent in the full-mutation group [108]. How-
ever, we found a high incidence (43 %) of mosaic FRAX
mutation in autistic patients, which requires confirmation
in other FRAX studies of large cohorts of ASD patients.
Deletion mutation
The molecular mechanism of the FRAX is based on the
expansion of a CGG repeat in the 5' UTR of the FMR1 gene
in the majority of fragile X patients. The instability of this
CGG repeats containing region is not restricted to the
CGG repeat itself but expands to the flanking region as
well. de Graaff et al 1996 [109] described four unrelated
fragile X patients mosaic for both a full mutation and a
small deletion in the CGG repeat containing region.
Sequence analysis of the regions surrounding the dele-
tions showed that both the (CGG)n repeat and some
flanking sequences were missing in all four patients. The
5' breakpoints of the deletions were found to be located
between 75–53 bp proximal to the CGG repeat. This sug-
gests the presence of a hot spots for deletions in the CGG
repeat region of the FMR1 gene and emphasizes the insta-
bility of this region in the presence of an expanded CGG
repeat [110-113]. All reported cases had fragile X pheno-
type (which may be an ascertainment bias), and the dele-
tion was usually a faint band suggesting a recent mutation
in a small population of cells. Our case had an unusual
Southern band pattern, consistent with the presence of
both a full mutation (3.7 and 5.8–7.9 kb; 200–900 r)and
a deleted (2.8 kb; 30 r) mutation with partial methylation.
Since immunohistochemical staining or Western blot
analysis was not performed to assess the FMRP produc-
tion it precludes clinical correlation.
A 6-year old mosaic permutation female carrier had
29,65,80,39 repeats. The autism spectrum disorder in our
patient may be due to diminished translational efficiency
in FMRP production. Tassone et al (2000) [114] [have
shown FMRP in 61% and 70% lymphocytes in two
females 91/2 years and 33 years of age with 103/33, 180/
30 repeats and IQ of 49 and 90, respectively. The first
patient has physical, cognitive, and behavioral features of
the fragile X phenotype but FMRP was in the normal
range, while the second patient also had FMRP level in the
normal range was treated for depression and has a history
of ovarian cyst, premature menopause at 27 years, and a
hysterectomy at 31 years. She also experienced social anx-
iety, panic attacks, mood swings, and mild obsessive com-
pulsive behaviors. Johnston et al. (2001) [115] recently
observed that emotional problems, including depression
and interpersonal sensitivity, were more likely to occur in
carrier females with >100 repeats. Austism spectrum dis-
order has been observed mostly in males with permuta-
tions [114,116,117]. The mosaic permutation in our
female patient was 80 repeats as the largest expansion
which is still below 100 repeats found in the affected cases
in literature. Clinical correlation in our permutation
mosaic case is hindered by the lack of FMRP studies and
even so, the tissue distribution of mosaicism and FMRP
profile would be the necessary phenotype determinant.
The significance of intermediate alleles found in 7/316
(Average age 4.36 years) of our patients requires further
exploration on larger independent samples as they may
raise the threshold for important developmental disabili-
ties and/or physical features [116].
The limitations of our retrospective study were a lack of
uniform clinical criterion for inclusion and limited behav-
ioral diagnostic information for purposes of dissecting the
phenotype. However, for autism diagnosis it may be reli-
able, as shown in a recent study [118] which examined the
UK General Practitioner Research Database (GPRD) and
found the diagnosis of autism among general practition-
ers in the UK had a high positive predictive value.
Conclusions
In our experience, the incidence of chromosome (3.33%)
and fragile-X (2.2%) abnormalities totals to 5.53% in a
population of patients with an indication of autism sent
for genetic testing. Since, 28% percent of chromosome
abnormalities detected in our study were subtle; a high
resolution cytogenetic study for ASD patients with a scru-
tiny of 15q11.2q13, 2q37 and Xp23.3 region should be
standard practice. The higher incidence of mosaic fragile-
X mutations with partial methylation in our ASD
population vs incidence of mosaicism in reported popula-
tions with fragile X syndrome [50% vs 15–40%], suggests
that faint bands and variations in the Southern band pat-
tern may occur rather frequently in fragile X positive autis-
tic patients. The mosaic FRAXA mutation with normal and
abnormal or partial methylation may also enhance the
threshold for autism spectrum disorder. Careful analysis
and high quality gels are required to rule out the type of
mutation in patients with autistic traits. FRMP estimates
in positive cases would be an extremely useful adjunct
especially in mosaic cases. Future studies are necessary to
corroborate the high incidence of mosaicism and their
role in ASD.
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